Acceptable Intakes (AIs) for 11 Small molecule N-nitrosamines (NAs)

Autor: Joel P. Bercu, Melisa Masuda-Herrera, Alejandra Trejo-Martin, Priyanka Sura, Robert Jolly, Michelle Kenyon, Rob Thomas, David J. Ponting, David Snodin, Gregor Tuschl, Stephanie Simon, Kathleen De Vlieger, Richard Hutchinson, Andreas Czich, Susanne Glowienke, M. Vijayaraj Reddy, Sandra Johanssen, Esther Vock, Nancy Claude, Richard J. Weaver

Publikováno v: Regulatory Toxicology and Pharmacology. :105415

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2ee8f7358994d33dfefa7e612fd27f78
https://doi.org/10.1016/j.yrtph.2023.105415

Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models

Autor: Raymond Pieters, Klaus Gjervig Jensen, Philip G. Hewitt, Jan Snoeys, Bob van de Water, B. Kevin Park, Ursula Klingmüller, André Guillouzo, Ian M. Copple, Dominic P. Williams, Michael J. Liguori, Cerys A. Lovatt, Paul Morgan, Satu Juhila, Eric A.G. Blomme, Magnus Ingelman-Sundberg, Dean J. Naisbitt, Gilles Labbe, Amy E. Chadwick, Christopher E. Goldring, Helga H.J. Gerets, Richard J. Weaver

Publikováno v: Nature Reviews Drug Discovery
Nature Reviews Drug Discovery, 2020, 19 (2), pp.131-148. ⟨10.1038/s41573-019-0048-x⟩
Nature Reviews Drug Discovery, Nature Publishing Group, 2020, 19 (2), pp.131-148. ⟨10.1038/s41573-019-0048-x⟩
NATURE REVIEWS DRUG DISCOVERY
Nature Reviews Drug Discovery, 19, 131-148

International audience; Drug-induced liver injury (DILI) is a patient-specific, temporal, multifactorial pathophysiological process that cannot yet be recapitulated in a single in vitro model. Current preclinical testing regimes for the detection of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::591bb427c638228c88d664ea664fd814
https://doi.org/10.1038/s41573-019-0048-x

Test systems in drug discovery for hazard identification and risk assessment of human drug-induced liver injury

Autor: Mikael Persson, Helga H.J. Gerets, Klaus Gjervig Jensen, Natalie Mesens, Jan Snoeys, B. Kevin Park, Tracy Walker, James L. Stevens, Catherine J. Betts, Gilles Labbe, Monday O. Ogese, Richard J. Weaver, Philip G. Hewitt, Michael J. Liguori, Eric A.G. Blomme, Satu Juhila

Publikováno v: Expert Opinion on Drug Metabolism & Toxicology. 13:767-782

Introduction: The liver is an important target for drug-induced toxicities. Early detection of hepatotoxic drugs requires use of well-characterized test systems, yet current knowledge, gaps and limitations of tests employed remains an important issue

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a59454364f73e9723c979fac2b6f4384
https://doi.org/10.1080/17425255.2017.1341489

A ligand-induced structural change in fatty acid–binding protein 1 is associated with potentiation of peroxisome proliferator–activated receptor α agonists

Autor: Richard J. Weaver, Biswaranjan Mohanty, Michelle L. Halls, Patrick Genissel, Craig Steven Clements, Laurent Vuillard, Christopher J.H. Porter, Indu R. Chandrashekaran, Rahul Chandrakant Patil, Bradley C. Doak, Martin Williams, Stephen J. Headey, O.V. Ilyichova, Bonan Liu, Martin J. Scanlon

Peroxisome proliferator–activated receptor α (PPARα) is a transcriptional regulator of lipid metabolism. GW7647 is a potent PPARα agonist that must reach the nucleus to activate this receptor. In cells expressing human fatty acid–binding prote

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6d0cd4ce2d9bfc97952bae843ac2ca7
https://europepmc.org/articles/PMC6416440/

Opportunities for use of one species for longer-term toxicology testing during drug development: A cross-industry evaluation

Autor: Keith Jones, Michael K. Pugsley, Helen Booler, Wendy Roosen, Aidan McGuire, Jacques Richard, David Jones, Noel Downes, Ruth A. Roberts, Ankie Schoenmakers, Mark Holbrook, Andreas Rothfuss, Julia Hui, Paul Brown, Marjorie A. Peraza, S.G. Moesgaard, Helen Prior, Sonja Beken, Meghan Flaherty, Leigh Ann Burns-Naas, Ian Kimber, Melissa Chapman, Lolke de Haan, Olaf Doehr, Richard J. Weaver, Paul Brooker, Nichola Gellatly, Brian Burlinson, Elisabeth Mortimer-Cassen, Hilla Kedar, Nancy Bower, Lucinda Weir, Andreas Mahl, Alison Wolfreys, Jennifer Harris, Alli Manninen, David W. Clarke, Warren Casey, Paul Baldrick, Fiona Sewell

Publikováno v: Regulatory Toxicology and Pharmacology. 113:104624

An international expert working group representing 37 organisations (pharmaceutical/biotechnology companies, contract research organisations, academic institutions and regulatory bodies) collaborated in a data sharing exercise to evaluate the utility

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e64937b1a362ed5fb5c52709a1d9219f
https://doi.org/10.1016/j.yrtph.2020.104624